Literature DB >> 25976666

Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat.

Saifudeen Ismael1, Sreeja Purushothaman, V S Harikrishnan, R Renuka Nair.   

Abstract

Left ventricular hypertrophy (LVH) is an independent risk factor for cardiac failure. Reduction of LVH has beneficial effects on the heart. LVH is associated with shift in energy substrate preference from fatty acid to glucose, mediated by down regulation of peroxisome proliferator-activated receptor-alpha (PPAR-α). As long-term dependence on glucose can promote adverse cardiac remodeling, it was hypothesized that, prevention of metabolic shift by averting down regulation of PPAR-α can reduce cardiac remodeling in spontaneously hypertensive rat (SHR). Cardiac response to stimulation of PPAR-α presumably depends on the type of ligand used. Therefore, the study was carried out in SHR, using two different PPAR-α ligands. SHR were treated with either fenofibrate (100 mg/kg/day) or medium-chain triglyceride (MCT) Tricaprylin (5% of diet) for 4 months. Expression of PPAR-α and medium-chain acylCoA dehydrogenase served as markers, for stimulation of PPAR-α. Both ligands stimulated PPAR-α. Decrease of blood pressure was observed only with fenofibrate. LVH was assessed from heart-weight/body weight ratio, histology and brain natriuretic peptide expression. As oxidative stress is linked with hypertrophy, serum and cardiac malondialdehyde and cardiac 3-nitrotyrosine levels were determined. Compared to untreated SHR, LVH and oxidative stress were lower on supplementation with MCT, but higher on treatment with fenofibrate. The observations indicate that reduction of blood pressure is not essentially accompanied by reduction of LVH, and that, progressive cardiac remodeling can be prevented with decrease in oxidative stress. Contrary to the notion that reactivation of PPAR-α is detrimental; the study substantiates that cardiac response to stimulation of PPAR-α is ligand specific.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25976666     DOI: 10.1007/s11010-015-2435-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  46 in total

1.  Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy?

Authors:  T Tanaka; K Sohmiya; K Kawamura
Journal:  J Mol Cell Cardiol       Date:  1997-01       Impact factor: 5.000

2.  Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system.

Authors:  Teayoun Kim; Qinglin Yang
Journal:  World J Cardiol       Date:  2013-06-26

3.  Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.

Authors:  Sreeja Purushothaman; Mb Mohamed Sathik; R Renuka Nair
Journal:  J Cardiovasc Pharmacol       Date:  2011-09       Impact factor: 3.105

Review 4.  Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future.

Authors:  Daniel H van Raalte; Min Li; P Haydn Pritchard; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

5.  The benefit of medium-chain triglyceride therapy on the cardiac function of SHRs is associated with a reversal of metabolic and signaling alterations.

Authors:  Motoyuki Iemitsu; Nobutake Shimojo; Seiji Maeda; Yoko Irukayama-Tomobe; Satoshi Sakai; Takeshi Ohkubo; Yukihisa Tanaka; Takashi Miyauchi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

6.  Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats.

Authors:  Wenyuan Zhao; Tieqiang Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Mol Cell Biochem       Date:  2008-06-26       Impact factor: 3.396

7.  Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids.

Authors:  Hiroshi Irie; Irvin B Krukenkamp; Joep F F Brinkmann; Glenn R Gaudette; Adam E Saltman; William Jou; Jan F C Glatz; Nada A Abumrad; Azeddine Ibrahimi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

8.  Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.

Authors:  Jian Zou; Kang Le; Suowen Xu; Jianwen Chen; Zhiping Liu; Xiaojuan Chao; Biao Geng; Jiani Luo; Siyu Zeng; Jiantao Ye; Peiqing Liu
Journal:  Mol Cell Endocrinol       Date:  2013-03-18       Impact factor: 4.102

9.  Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.

Authors:  Nathan K Lebrasseur; Toni-Ann S Duhaney; Deepa S De Silva; Lei Cui; Peter C Ip; Lija Joseph; Flora Sam
Journal:  Hypertension       Date:  2007-07-02       Impact factor: 10.190

10.  Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.

Authors:  Gerard T Chew; Gerald F Watts; Timothy M E Davis; Bronwyn G A Stuckey; Lawrence J Beilin; Peter L Thompson; Valerie Burke; Philip J Currie
Journal:  Diabetes Care       Date:  2008-05-16       Impact factor: 19.112

View more
  4 in total

1.  Reactivation of fatty acid oxidation by medium chain fatty acid prevents myocyte hypertrophy in H9c2 cell line.

Authors:  Saifudeen Ismael; R Renuka Nair
Journal:  Mol Cell Biochem       Date:  2020-09-30       Impact factor: 3.396

2.  Mitoprotective antioxidant EUK-134 stimulates fatty acid oxidation and prevents hypertrophy in H9C2 cells.

Authors:  Sreeja Purushothaman; R Renuka Nair
Journal:  Mol Cell Biochem       Date:  2016-08-11       Impact factor: 3.396

3.  Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure.

Authors:  Bin Tang; Jin-Guo Zhang; Hong-Yong Tan; Xi-Qing Wei
Journal:  Biosci Rep       Date:  2018-05-22       Impact factor: 3.840

4.  Interaction between ACOT7 and LncRNA NMRAL2P via Methylation Regulates Gastric Cancer Progression.

Authors:  Huiqin Feng; Xiaojian Liu
Journal:  Yonsei Med J       Date:  2020-06       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.